Hundreds of thousands of patients worldwide are waiting for a kidney transplant, and millions undergo life-saving dialysis treatments. Every year, 10% of patients are removed from the waiting list due to a significant deterioration in their health or death. The cause is the critical shortage of organs available for transplant. At the same time, the demand for blood is rapidly increasing, and its short 40-day shelf life means that 1.3 million liters are discarded each year.
Our mission is to harness the potential of nanotechnology to revolutionize transplantation medicine and transfusion medicine by creating innovative organ perfusion systems and a safe, effective blood substitute.
We have developed an innovative solution aimed at increasing the number of available transplant organs by utilizing kidneys from donors after prolonged circulatory death (Donors after Circulatory Death). With this technology, we aim to address the organ shortage problem and increase organ availability for patients worldwide.
We have developed an innovative solution aimed at increasing the number of available transplant organs by utilizing kidneys from donors after prolonged circulatory death (Donors after Circulatory Death). With this technology, we aim to address the organ shortage problem and increase organ availability for patients worldwide.
NanoSanguis, a subsidiary of NanoGroup, is a biotechnology company focused on leveraging the potential of nanotechnology in medicine. Founded by a team of scientists from the Warsaw University of Technology, the company combines advanced scientific knowledge with an unconventional approach to develop innovative solutions in the fields of transplantation and transfusion medicine. By applying state-of-the-art technologies, we aim to establish a new standard, meeting the needs of patients worldwide.
A medical doctor specializing in clinical pharmacology, former advisor to the Minister of Health on pharmaceutical policy. He negotiated Poland’s accession to the EU in the field of pharmaceuticals and was responsible for implementing EU directives in pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products. Owner of a consulting firm collaborating with international pharmaceutical companies on introducing new technologies to the Polish market.
Przemysław Mazurek is an experienced executive and innovator in the biotechnology sector, focusing on the development and commercialization of impactful breakthrough medical technologies. As the
President of the Management Board of NanoGroup S.A., he strategically leads the company’s growth, driving the implementation of innovative nanotechnology-based solutions with a clear vision for market
leadership.
His career in the medical sector began in 2004, when he successfully restructured and expanded one of the most dynamic medical centres in the Podkarpacie region, setting new standards for patient service. He co-founded Poland's first online medical appointment booking system and played a key role in establishing the region’s first and only infertility treatment clinic, where he served as President until 2009.
As Vice President of PZU ZdrowieS.A., he was responsible for the development of health insurance, leading the creation of the largest medical Third Party Administrator (TPA) in Poland. He built a nationwide healthcare provider network, implementing an innovative financial model that connected over 1,550 medical partners.
From 2015 to 2018, as Head of the Health Insurance Department at PZU Group S.A., he was responsible for strategy development, implementation, and further growth, leading to an additional budget of 650 million PLN. He also co-developed Poland’s first drug insurance product, achieving significant success.
Since 2015, he has been actively engaged in wealth management, offering strategic consulting in finance and business management. He has served on multiple boards in the healthcare sector and continues to advise organizations on financial strategies, healthcare innovation, and business development.
A graduate of the Warsaw School of Economics and the prestigious Advanced Management Program at IESE Business School – University of Navarra in Spain. Mr. Mazurek brings a strong academic foundation to his extensive practical experience.
Dr. Stefan Bogusławski has been conducting research and consulting in the broad field of healthcare for almost 30 years. His professional experience includes many years of leadership at Sequence and PEX PharmaSequence – Polish advisory and research companies specializing in the healthcare market, as well as managing the Polish branch and the Central European region at IMS Health (now IQVIA) and the research company Azyx Polska. He is the author of numerous presentations at conferences in Poland and abroad, as well as publications in both general and specialized media on the Polish healthcare market, particularly the pharmaceutical market. A graduate of the Medical University of Warsaw, he obtained his medical degree in 1985. He has participated in numerous domestic and international courses and training in general management (including INSEAD), finance, marketing, communication, sales skills, and human resource management. Stefan Bogusławski also works as a senior specialist at the Department of Monitoring and Analysis of the Health Status of the Population at the National Institute of Public Health – PZH – PIB. He has been repeatedly included in the “Top 100 Most Influential People in the Polish Healthcare System” list, published by Puls Medycyny.
Co-founder of Top Consulting S.A., one of the oldest consulting companies in the Polish market. He has over 25 years of international experience in investment consulting, capital raising for companies, market acquisitions, and company management. For many years, he was a consultant for American financial organizations on Wall Street in New York, including those listed on the NASDAQ and NYSE stock exchanges. He has advised, among others: Household International in preparing acquisition strategies and obtaining a banking license in Poland, Wussler Group, Ted Turner Pictures’ partner in attempting to acquire NTV, the largest private TV station in Russia, Eiffage Construction in acquiring Mitex, the largest construction company at the time, and Industrial Union of Donbas, an industrial group in Ukraine. He has been a member, chairman, and president of the supervisory boards of numerous companies listed on the Warsaw Stock Exchange, including Bauma S.A. (now ULMA S.A.), Computerland Poland S.A. (now Signity), and PolAqua S.A. He is also a co-founder of the Start-up Hub Poland Fund. He graduated from the Faculty of Journalism and Political Science at the University of Warsaw and International Relations at the University of Hawaii in Honolulu.
A medical doctor who also completed an MBA, an effective manager. Organizer of business models and company structures – experienced in building and developing companies as well as leading corporate restructuring processes. Former director and motivator of large companies and teams. Recognized as a leader in the Polish pharmaceutical industry. Member of the Supervisory Board of American Heart of Poland SA and President of WSiP SA. Previously, President of AstraZeneca Sp. z o.o., President of Fournier Polska Sp. z o.o., Sales Director at Pfizer Polska Sp. z o.o., Sales Director and Marketing Director at MSD Poland – also involved in clinical research.
Transplantation still faces many challenges related to organ preservation. Many kidneys currently do not meet the criteria required for transplantation due to damage caused by ischemia. At NanoSanguis, we have developed an innovative solution – a perfusion fluid and a device based on nanoparticles, which aims to revolutionize the current standard in this field.
The NanOX system is a groundbreaking approach to organ preservation, offering an advanced alternative to traditional methods. Designed to function under sub- and normothermic conditions, the system closely mimics natural physiological processes, ensuring optimal conditions for organ preservation and regeneration.
A key element of the NanOX technology is the use of perfluorocarbon nanoparticles. These synthetic nanoparticles mimic the functions of red blood cells, transporting oxygen and removing carbon dioxide in a manner nearly identical to natural human blood. This helps support the metabolism of organs and even enables their regeneration, increasing the likelihood of successful transplantation. Furthermore, our nanoparticles are easy to produce and can be manufactured on a large scale.
The kidney perfusion system developed by our scientists offers several unique advantages:
NanOX is not just about numbers – it is about saving lives and improving the quality of life for patients worldwide. With this revolutionary organ preservation technology, NanoSanguis strives to set a new standard in transplantation.
Do you set ambitious scientific goals for yourself? Are you interested in participating in medical projects in the fields of biotechnology and nanotechnology?
NanoGroup is a platform for expertise and specialists united by the belief that breakthrough technologies addressing pressing global challenges can be created and developed in Poland.
If you’d like to join our team, get in touch with us!
NanoSanguis
S.A
ul. Rakowiecka 36
02-532 Warszawa
NIP: 7010537389
REGON: 363505173
KRS: 0000595165
Office
+48 604 741 303
District Court for the Capital City of Warsaw, XIII Commercial Division of the National Court Register KRS: 0000595165, Share capital (fully paid) 4,068,587.00 PLN